Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In this study an attempt is made to propose a working clinical classification and staging of adult non-Hodgkin's lymphoma (NHL) which brings out both primary site and extent of disease. Unlike childhood NHL, where histopathology is uniformly of unfavourable type, this clinical staging system seems to have a prognostic value when applied with reference to different histology groups of working formulation. Based on the experience of staging of childhood NHL as proposed earlier, 304 cases of adult NHL above 14 years of age seen at Kidwai Memorial Institute of Oncology, Bangalore, India, over a period of 5 years (1981-1985) are first categorized according to primary site (initial bulky site at presentation): (1) peripheral nodal (n = 181; (2) extranodal (excluding gastrointestinal tract; n = 48); (3) abdominal (including gastrointestinal tract; n = 46), and (4) mediastinal (n = 29). Each group is further staged according to the extent of the disease. Once categorized into various clinical groups, the Ann Arbor Clinical staging fits very well only with the peripheral nodal group, the major group, although not suitable for other clinical groups.
 ...
PMID:Clinical staging of adult non-Hodgkin's lymphoma. 236 60

Forty-seven cases of adult non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) seen at the University of Benin Teaching Hospital between 1975 and 1987 have been analysed with respect to the presenting features, management and survival. There is a preponderance of males over females (4.4:1 for NHL and 9:1 for HD). NHL was commonly diagnosed in the 41-50 year age group and HD in the 21-30 year age bracket. Lymphadenopathy was observed in all patients at the time of presentation, mainly generalized (48.1%) in NHL and cervical (65%) in HD. The poorly differentiated lymphocytic (29.6%) and undifferentiated (22.2%) types of NHL and the mixed cellularity type (40%) of HD are the most frequent histopathological types. The COP regime was the most frequently used therapeutic regimen. The results of treatment were poor mainly because of late presentation, inadequate supply of drugs, the high default rate and relative lack of radiotherapeutic facilities.
 ...
PMID:The malignant lymphomas in Benin City, Nigeria. 275 94

In 2 randomised, prospective Eastern Co-operative Oncology Group trials, the frequency of central nervous system (CNS) involvement after chemotherapy in 347 adults with stage III and IV unfavourable-histology, non-Hodgkin's lymphoma was 8.4%. The frequency varied from 0% in diffuse mixed lymphoma to greater than 30% in lymphoblastic and diffuse-undifferentiated lymphoma. Of the 42% of patients who achieved complete remission after chemotherapy, CNS involvement developed in 5.4% during relapse, but in only 2.7% was the CNS the sole site of relapse. CNS lymphoma arose in 6.6% of 197 patients with diffuse histiocytic lymphoma, but in only 1 subject (1%) was the CNS the sole site of relapse. Therefore, CNS prophylaxis is not indicated for the common diffuse-histology subtypes of adult non-Hodgkin's lymphoma including diffuse-histiocytic, diffuse-mixed and diffuse poorly differentiated lymphocytic lymphoma. The relatively high frequency of CNS lymphoma in lymphoblastic and diffuse undifferentiated lymphoma justify further studies of CNS prophylaxis.
 ...
PMID:Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated? 614 3

Levels of serum copper in 34 patients with adult non-Hodgkin's lymphoma at different phases of the disease have been studied. All of the patients were evaluated with complete blood counts, sedimentation rate, gallium scintigraphy, liver and bone marrow biopsies, lymph node biopsy, and laparoscopy. The level of serum copper was significantly elevated in non-responding or relapsing patients (mean 191.06 micrograms/dl), and correlated with the estimated tumor burden. Serum copper levels within normal range were found in patients in complete remission (mean 114.76 micrograms/dl). Age- and sex-matched normal controls also showed serum copper levels within normal range (mean 112.81 micrograms/dl). It is proposed that serial measurements of serum copper level may be of use in: (1) monitoring the remission status of patients with non-Hodgkin's lymphoma, (2) detecting early relapse of non-Hodgkin's lymphoma, and (3) contrary to previous reports by Hrgovcic et al., the level of serum copper seems to be related to the disease activity of histiocytic lymphoma.
 ...
PMID:Serum copper levels in non-Hodgkin's lymphoma. 698 85

To determine whether kinase (TK) isozyme status adds clinically useful information in adult non-Hodgkin's lymphoma (NHL), we have analyzed peripheral blood plasma and lymphocytes of 44 patients with NHL for either TK1 or TK2 isozyme activity. On the basis of isozyme status, patients could be divided into two groups that did not differ significantly with respect to known determinants for survival. The median survival of patients exhibiting peripheral blood TK1 thymidine kinase activity was 40 wk and that of individuals with TK2 activity was in excess of 200 wk. These data suggest that peripheral blood TK1 isozyme is a useful independent biochemical marker for a subgroup of NHL who respond poorly to current therapy and thus require new therapeutic approaches.
 ...
PMID:Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. 729 3

In order to obtain valid data on the pattern, frequency and prognostic significance of autoimmune derangements in non-Hodgkin's lymphoma (NHL) we studied 626 consecutive adult NHL patients participating in a population-based lymphoma registry. A total of 86 patients, corresponding to 13.7%, showed autoimmune phenomena (AP). Of these, 7.8% exhibited clinical autoimmune phenomena (CAP), and 5.9% showed immunohaematological phenomena (IHP). The distribution of histological subgroups of NHL in the AP and non-AP patients was similar. The same holds true for the CAP and IHP patients. A slight, non-significant overrepresentation of NHL, T-cell phenotype was found in patients with AP. CAP preceded the diagnosis of NHL in most patients, whereas IHP was associated with active lymphoma disease. AP as a whole did not predict for time to complete response, time to relapse or for survival. The finding that IHP patients relapsed earlier than CAP patients was not reflected in a significant difference in survival.
 ...
PMID:Autoimmune phenomena in non-Hodgkin's lymphoma. 853 98

In several types of solid tumours, circulating antibodies to p53 are seen in about a third of cases with a p53 mutation, but are absent in cases without p53 mutation. Therefore detection of those antibodies has relatively low sensitivity but high specificity in the detection of p53 mutations. We looked for circulating p53 antibodies by ELISA in 56 adult non-Hodgkin's lymphoma (NHL) and 80 multiple myeloma cases. A certain or highly probable p53 mutation was found by SSCP analysis, immunocyto- or immunohistochemistry in 8/35 (23%) NHL cases and 2/19 (10%) MM cases analysed by these techniques. None of the 80 MM cases and only one of the 56 cases of NHL had circulating p53 antibodies. The positive case had Burkitt's lymphoma and a p53 missense mutation at codon 273. Thus, very few MM and NHL patients with a p53 mutation develop p53 antibodies and this test does not appear to be useful in haematological malignancies.
 ...
PMID:Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma. 945 Aug 8

Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. High-dose chemotherapy followed by transplantation of either autologous marrow (ABMT) or peripheral stem cells (PBSCT) offers such patients a new possibility of cure. To patients younger than 60 years and without contraindications high-dose chemotherapy should be offered in case of relapse and bad prognosis. The PARMA-study demonstrated, that high-dose chemotherapy with subsequent autologous stem cell transplants is superior to conventional chemotherapy for relapsing patients. However high-dose chemotherapy in first complete or partial remission followed by ABMT and PBSCT as post-remission therapy for adult NHL has yielded only similar results randomized to those achieved with conventional chemotherapy in several prospectively studies. This approach should be limited to patients with bad prognostic factors (high-intermediate or high-risk groups according to the International Prognostic Factor Project). The success of ABMT and PBSCT in treating these diseases mandates exploration of the best high-dose chemotherapy, the use of autologous or allogenic bone marrow resp. peripheral stem cell for haematopoietic reconstitution and technical aspects such as purging of tumor cells, the short- and long-term transplant-related mortality continues to be a major concern.
 ...
PMID:[Therapy of highly malignant non-Hodgkin lymphoma with high-dose chemotherapy and stem cell transplantation]. 970 88

We report a 34-year-old male with relapsed non-Hodgkin's lymphoma (NHL) after autologous peripheral blood stem cell transplantation successfully treated with unrelated cord blood transplantation (CBT). The conditioning regimen included 12 Gy total body irradiation and cyclophosphamide. After the conditioning, a total of 3.14 x 10(7)/kg cord blood nucleated cells was infused on 14 February 2000. An absolute neutrophil count greater than 5 x 10(8)/l and a self-sustained platelet count greater than 50 x 10(9)/l were achieved on days 21 and 43, respectively. During the follow up period, grade I acute graft-versus-host disease (GVHD) and limited chronic GVHD occurred, but both were successfully treated with a dose modification of cyclosporine. After a follow-up period of 16 months, the patient is alive and free of disease. To our knowledge this is the first report of a successful unrelated CBT for an adult NHL patient who relapsed after autologous transplantation.
 ...
PMID:Successful unrelated cord blood transplantation for relapse after autologous transplantation in non-Hodgkin's lymphoma. 1200 75

All cases S16 years of age with a histological diagnosis of non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) presented in Scotland between 1 January 1994 and 31 December 1996 were registered prospectively in the Scotland and Newcastle Lymphoma Group database by a process of total registration. The census population of Scotland in 1996-1997 was 5.1 million. One thousand seven hundred and sixty three patients were registered with NHL and 350 patients with HD. These patients have been followed up for a median of 47 months in the case of NHL and 51 months for HD cases. Actuarial 5-year survival for adult NHL was 35% and for HD, 75%. Outcome for both NHL and HD was particularly poor in the population over 60 years with median survival of 18 months for NHL and 27 months for HD. When analysis of survival was related to degree of material deprivation using the Carstairs score a significantly poorer survival was seen for NHL with increasing deprivation that could not be explained by a different pattern of age or stage at presentation. Deprivation had no impact on incidence or survival in HD. Analysis of impact of caseload of the physician initiating therapy showed no significant difference in 5-year survival.
 ...
PMID:Total registration of non-Hodgkin's lymphoma and Hodgkin's disease in Scotland: effect of deprivation and caseload on outcome. 1291 38


1 2 Next >>